Understanding attention deficit disorder: a neuroscience prospective

Today’s ready access to electronic devices and the internet often substitute for social interaction. Such situation, if it starts in early childhood, in certain vulnerable individuals, who crave immediate rewards, can decrease the ability to maintain prolonged attention (1) and tolerate delayed gratification, thus reinforcing future addictive behaviors (2). Once established, these behaviors, such as attention deficit hyperactivity disorder (ADHD), may persist into adulthood. ADHD is one of the most common reasons for referring children to mental health facilities. Generally, parents seek professional help for their children after the school suggests that their child has difficulties. These difficulties may be related to academic performance, behavior, or both. Research data support the idea that children with attention deficit disorder often come from families with attention deficit in one or both parents (3). Very recent data indicate a significant genetic predisposition for this disorder. Seventy percent of children who have this disorder will have the disorder as teenagers, and about 40%-60% will still have the disorder as adults, and although genetic studies have not isolated a gene for ADHD, there may be several genes contributing to the vulnerability for developing this disorder. For example, twin studies have shown a significant heritability for ADHD (4) as high as 76%. In addition, the parents and siblings of children with ADHD have an ADHD diagnostic probability 4-5 times higher than the general population, and boys are more vulnerable than girls (5). Based on these data, it might appear that ADHD is easily diagnosed and, thus, simple to treat, but we still must question the methods and criteria used for diagnosing ADHD. Currently, clinical interviews and collateral histories from parents and teachers drive the standards. Only occasionally do we use objective assessments, such as continuous performance tasks and neuropsychological assessments, to evaluate whether or not a child can sustain attention, and whether their deficits lie in either or both auditory and visual domains. Various factors may play a role in sustaining attention. These may include: motivation, concurrent anxiety, lack of sleep, low blood glucose, medication, and family collaboration (6). Clinicians consider and evaluate three major symptom groups for diagnosing ADHD: inattention, hyperactivity, and impulsivity. Each category describes particular symptoms; for example, inattention may involve an inability to finish tasks, organize, and sustain efforts as well as forgetfulness and distractibility. Hyperactivity is defined as being fidgety, inability to sit still, and motoric hyperactivity – excessive running, climbing, and moving. Impulsivity involves excessive talking, answering without thinking, inability to wait one’s turn, interrupting, and so on. Both the DSM IV and the ICD 10 provide guidelines for the frequency and duration of the symptoms in these diagnostic categories, and both generally agree on the necessary number of symptoms before someone receives the diagnosis of ADHD. Nevertheless, it should be noted that these symptoms may be defined and scored by individuals that are untrained in this process. Therefore, we need to question the reliability and validity of such unidimensional data.

On the other hand, neuroscientists focus primarily on the relationship between the symptoms and brain structures such as the dorsal lateral prefrontal cortex, ventral lateral prefrontal cortex, insula, anterior cingulate, and default networks and functions linked to neurotransmitter systems (7-10). They generally agree that ADHD patients primarily struggle with improper utilization of the neurotransmitter dopamine, and, to a lesser extent, norepinephrine (11,12). Dopamine significantly affects numerous behaviors, including movement modulation, cognition, mood, and attention. In ADHD cases primarily involving dopamine, clinical medication interventions can increase dopamine’s availability, significantly improve continuous task performance, decrease hyperactivity, and increase behavior management in school. Although methylphenidate is considered the first-line medication for attention deficit disorder hyperactivity in children and adults, many children are unresponsive to this medication. We should ask ourselves why. Recent neuroscientific studies describe three types of
attentional networks: ventral, dorsal, and default executive control. Although these network functions overlap (13), if any network deregulates, it will contribute to some clinically observable aspects of ADHD. Therefore, if we learn to understand the identified risk factors that lead to the clinical development of this disorder, ie, in utero drug exposure, low birth weight, premature delivery, endocrine deregulation, early developmental neglect, environmental toxins, head trauma, and genetic vulnerability, we can understand the vulnerability and deregulation of these networks (5).

Quantitative EEG has helped define ADHD's physiological underpinnings by clearly identifying electrical patterns such as increased frontal slowing and excessive frontal theta (14) that correlate with inability to sustain attention (15). Based on this information, the Food and Drug Administration recently approved qEEG as an adjunct assessment tool for the diagnosis of ADHD (16). From objective qEEG measures, new data suggest that varying electrical patterns may fit the definition of childhood inattention, in the ADHD category (13), and point to a heterogeneous ADHD population (17). The challenge lies in understanding how different patterns respond to different treatments.

Then we should ask what happens to the child as they become an adult? To answer this question, we need to understand the adult presentation of attention deficit disorder (18,19). Generally, although the specific ADHD symptoms for children and adolescents differ from adults, we can observe and define similar behaviors. In adults, inattention and impulsivity are less evident; rather their symptoms manifest as poor concentration, distractibility, an inability to finish tasks, and poor planning, which, in turn, may become an inability to maintain employment (20), and because these individuals are often drawn to fast-paced, highly stimulating work with immediate rewards, they may leave a job out of boredom and prefer employment in the stock market, sales, emergency department, or creative jobs that give them ample freedom (21,22). In addition, these individuals often engage in self-destructive behaviors such as substance abuse, gambling, and other immediately rewarding behaviors. Simply stated, they have difficulty delaying gratification. We can effectively treat these adults, just as we would treat a child, by combining medications, such as dopamine and, perhaps, norepinephrine that target their symptoms, with behavioral and psychological interventions (18).

Nevertheless, our current data support the idea that, in many cases, ADHD persists throughout one's life: when untreated, ADHD can have significant psychiatric comorbidities that include anxiety, depression, substance abuse, conduct disorder, and bipolar disorder (23). Therefore, to effectively treat these individuals, we must establish a clear diagnosis using multi-dimensional diagnostic evaluations that address patients from bio-psychosocial and spiritual points of view. Moreover, comprehensive, early developmental, familial, functional, neuropsychological, and neuropsychological assessments are vital. The converging data from these various approaches will provide a better understanding of how the patients perceive their environment, and how they respond to stress, solve problems, and react to rewards or punishment. Afterwards, when considering medication therapies, we can choose according to patient-specific pharmaco-dynamic and pharmo-kinetic data. Later, to further tailor the patient's medication paradigm, we can use qEEG acute medication challenge studies and neuro-behavioral assessments (24,25). Recent data show that methylphenidate and atomoxetine differ in their effects; methylphenidate decreases brain noise by increasing signal-to-noise ratio and enhances overall performance, while atomoxetine increases specific performance and the salience of task-specific signals (26,27). This pharmaco-therapeutic approach may enhance medication effects and avoid prolonged clinical trials that can last for days and weeks with significant hardship for the patients and their families.

References:
1 Swing EL, Gentile DA, Anderson CA, Walsh DA. Television and video game exposure and the development of attention problems. Pediatrics. 2010;126:1-16. Medline:20603258 doi:10.1542/peds.2009-1508
2 Bavelier D, Green CS, Han DH, Renshaw PF, Merzenich MM, Gentile DA. Brains on video games. Nat Rev Neurosci. 2011;12:763-8. Medline:22095065 doi:10.1038/nrn3135
3 Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1313-23. Medline:15950004 doi:10.1016/j.biopsych.2004.11.024
4 Franke B, Neale BM, Faraone SV. Genome-wide association studies in ADHD. Hum Genet. 2009;126:13-50. Medline:19384554 doi:10.1007/s00439-009-0663-4
5 Gershon J, Gershon J. A meta-analytic review of gender differences in ADHD. J Atten Disord. 2002;5:143-54. Medline:11911007 doi:10.1177/108705470200500302
6 Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry. 2005;57:1215-20. Medline:15949990 doi:10.1016/j.biopsych.2004.10.020
7 Castellanos FX, Margulies DS, Kelly C, Uddin LQ, Ghaffari M,
Kirsch A, et al. Cingulate-precuneus interactions: a new locus of dysfunction in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63:332-7. Medline:17888409 doi:10.1016/j.biopsych.2007.06.025

8 Castellanos FX, Prol E. Large-scale brain systems in ADHD: beyond the prefrontal striatal model. Trends Cogn Sci. 2012;16:17-26. Medline:22169776 doi:10.1016/j.tics.2011.11.007

9 Schulz KP, Newcorn JH, Fan JH, Tang CY, Halperin JM. Brain activation gradients in ventrolateral prefrontal cortex related to persistence of ADHD in adolescent boys. J Am Acad Child Adolesc Psychiatry. 2005;44:47-54. Medline:15608543 doi:10.1097/01.chi.0000145551.26813.f9

10 Sowell ER, Thompson PM, Welcome SE, Henkenius AL, Toga AW, Peterson BS. Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Lancet. 2003;362:1699-707. Medline:14643117 doi:10.1016/S0140-6736(03)14842-8

11 Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry. 1999;46:1234-42. Medline:10560028 doi:10.1016/S0006-3223(99)00192-4

12 Tripp G, Wickens JR. Research review: dopamine transfer deficit: a neurobiological theory of altered reinforcement mechanisms in ADHD. J Child Psychol Psychiatry. 2008;49:691-704. Medline:18081766 doi:10.1111/j.1469-7610.2007.01851.x

13 Cortese S. The neurobiology and genetics of Attention-Deficit/Hyperactivity Disorder (ADHD): What every clinician should know. Eur J Paediatr Neurol. 2012;16:422-33. Medline:22306277 doi:10.1016/j.ejpn.2012.01.009

14 Chabot RJ, Merkin H, Wood LM, Davenport TL, Serfontein G. Sensitivity and specificity of QEEG in children with attention deficit or specific developmental learning disorders. Clinical Electroencephalogr. 1996;27:26-34. Medline:8719499

15 Ams M, Conners CK, Kraemer HC. A decade of EEG theta/beta ratio research in ADHD a meta-analysis. J Atten Disord. 2013;17:374-83. Medline:23086616 doi:10.1177/1087054712460087

16 Barkley RA. Editor’s Note: A cautionary note about using the EEG for clinical diagnosis of ADHD. ADHD Rep. 2013;21:15. doi:10.1521/adhd.2013.21.6.15

17 Martin CN, Konopka LM. Community-based electrophysiological abnormalities in children with adhd: translating research findings into a clinical setting. Act Nerv Super. 2011;53:129-40.

18 Camilleri N, Makhoul S. ADHD: from childhood into adulthood. Malta Medical Journal. 2013;25:2-7.

19 Kessler RC, Adler L, Barkley R, Biederman J, Conners C, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716-23. Medline:16585449 doi:10.1176/appi.ajp.163.4.716

20 Biederman J, Faraone SV. The effects of attention-deficit/hyperactivity disorder on employment and household income. Medscape General Medicine. 2006;8:12. Medline:17406154

21 Swift KD, Hall CL, Marinutto V, Redstone L, Sayal K, Hollis C. Transition to adult mental health services for young people with Attention Deficit/Hyperactivity Disorder (ADHD): a qualitative analysis of their experiences. BMC Psychiatry. 2013;13:74. Medline:23497082 doi:10.1186/1471-244X-13-74

22 White HA, Shah P. Creative style and achievement in adults with attention-deficit/hyperactivity disorder. Pers Individ Dif. 2011;50:673-7. doi:10.1016/j.paid.2010.12.015

23 Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001;40:147-58. Medline:11211363 doi:10.1097/00004583-200102000-00009

24 Konopka LM, Poprawski TJ. Quantitative EEG studies of attention disorders and mood disorders in children. In: Ivanenko A, editor. Sleep and psychiatric disorders in children and adolescents. New York: Informa Healthcare. 2008. p. 293-304.

25 Lubar JF, Swartwood MO, Swartwood JN, Timmermann DL. Quantitative EEG and auditory event-related potentials in the evaluation of attention-deficit/hyperactivity disorder: Effects of methylphenidate and implications for neurofeedback training. J Psychoed Assess. 1995;34:143-60.

26 Chamberlain SR, Del Campo N, Dowson J, Muller U, Clark L, Robbins TW, et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry. 2007;62:977-84. Medline:17644072 doi:10.1016/j.biopsych.2007.03.003

27 Marquand AF, De Simoni S, O’Daly OG, Williams SCR, Mourao-Miranda J, Mehta MA. Pattern classification of working memory networks reveals differential effects of methylphenidate, atomoxetine, and placebo in healthy volunteers. Neuropsychopharmacology. 2011;36:1237-47. Medline:21346736 doi:10.1038/npp.2011.9